Blood Test Predict Mortality: 14 Alarming Biomarkers Revealed
The ability to use a blood test to predict mortality could soon help doctors tailor treatment plans more effectively than ever before. A new study looking at biomarkers in the blood concludes that more accurately estimating mortality over a 5 to 10 year period might soon be possible — a development with significant implications for clinical medicine, personalized care, and clinical trial design. This emerging science of blood test predict mortality research could reshape how medicine approaches aging and preventive care.
As it stands, doctors can predict mortality within the final year of life with some degree of accuracy. However, predicting it over longer periods has not yet been possible. A group of scientists who recently published a paper in Nature Communications believes they are now on the path toward a reliable predictive blood test.
Why a Blood Test to Predict Mortality Matters
A blood test that could predict whether someone is likely to live 5 or 10 more years would give doctors important information for treatment decisions. For instance, clinicians would be able to determine if an older adult is healthy enough for surgery or identify those in most need of medical intervention before significant health deterioration occurs. Developing a reliable blood test predict mortality tool represents one of the most exciting frontiers in modern predictive medicine.
A test like this could also benefit clinical trials significantly — scientists could monitor how an intervention impacts mortality risk without having to run trials until enough participants die, potentially accelerating the pace of research and improving study design.
Currently, blood pressure and cholesterol levels can give doctors an impression of a person’s likely lifespan. However, in older adults these measures become less useful. Counterintuitively, for people aged 85 or over, higher blood pressure and higher cholesterol levels are actually linked with lower mortality risk — highlighting the need for more nuanced predictive tools.
The Study Behind the Blood Test Predict Mortality Research
The largest blood test predict mortality study of its kind drew data from 44,168 people aged 18 to 109. Scientists from Brunel University London in the United Kingdom and Leiden University Medical Center in the Netherlands set out to identify blood biomarkers that could address this gap in predictive medicine.
During the follow up period, 5,512 of these people died. The team initially identified metabolic markers associated with mortality and created a scoring system to predict when a person might die. They then compared the reliability of this scoring system with a model based on standard risk factors, studying an additional 7,603 individuals, 1,213 of whom died during follow up.
The 14 Biomarkers
After analyzing a long list of metabolites, the researchers settled on 14 biomarkers independently associated with mortality. This combination of 14 markers forms the foundation of the blood test predict mortality scoring system.
Higher concentrations of some biomarkers — including histidine, leucine, and valine — are associated with decreased mortality risk. Conversely, lower concentrations of others — such as glucose, lactate, and phenylalanine — are associated with increased mortality risk.
The scientists demonstrated that the combination of biomarkers could predict mortality equally well in both males and females, and across several age groups. All 14 biomarkers showed consistent associations with mortality across all demographic strata examined.
The biomarkers identified are involved in a wide range of bodily processes including fluid balance and inflammation. Most have been individually linked to mortality risk in previous studies — but this was the first time researchers demonstrated their predictive power when combined into a single model.
The Road Ahead
The study authors acknowledge certain limitations. They were only able to analyze hundreds of the thousands of metabolites present in human serum. Including more metabolites in future analyses would, the authors predict, result in the identification of many more mortality associated biomarkers and improved risk prediction.
Study co author Dr. Fotios Drenos expressed hope that in the near future, researchers will be able to understand which biomarkers can be modified — perhaps through lifestyle improvements or medication — to lower the risk of death before significant health deterioration occurs. As research advances, a blood test predict mortality approach could become as routine as checking cholesterol levels today.
Although a blood test predict mortality tool would not be immediately suitable for general public use, it could eventually evolve into routine clinical practice in the same way that genetic testing has developed over recent decades. Perhaps, in the future, the question will not be “How long will I live?” but rather “Do I want to know?”
Conclusion
The development of a validated blood test predict mortality tool would represent a transformative shift in how doctors plan long term care for patients of all ages. This kind of biomarker research directly informs how clinical trials are designed and conducted. Our introduction to clinical trials explains how studies like this one move from initial discovery toward real world clinical application.
For those interested in how metabolic health connects to mortality risk, our article on treating hypertension explores the genetic and biomarker based approaches being developed to predict and prevent cardiovascular disease.
According to Nature Communications, the journal in which this study was published, large scale biomarker studies represent one of the most promising frontiers in predictive medicine and personalized health research.
.
Source: Medical News Today